Revelation Biosciences, Inc. announced that it has entered into a security purchase agreement for the issuance of one Series A Preferred Stock, par value $0.001 per share at a price of $5,000 per share for gross proceeds of $5,000 on December 19, 2022. The transaction included participation from Chief Executive Officer James Rolke of the company. The securities represented in the transaction have not been registered under 4(a)(2) of the Securities Act of 1933, as amended.